News | October 17, 2023
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin enters into BTA with Lupin Manufacturing Solutions
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
Pirfenidone Capsules had estimated annual sales of USD 95 million in the US
This product will be manufactured at Lupin's Pithampur facility in India
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Subscribe To Our Newsletter & Stay Updated
